Johnson & Johnson
JNJ
$271.04
+0.86%
Johnson & Johnson is the world's largest diversified healthcare company, operating through two segments — Innovative Medicine (pharmaceuticals focused on immunology, oncology, and neurology) and MedTech (surgical, orthopedic, and interventional devices) — following the 2023 spin-off of its consumer health business, Kenvue. As a scale leader with roughly 140,800 employees and a portfolio spanning blockbuster drugs like oncology and immunology franchises plus a broad device platform, J&J occupies a defensive, cash-generative position at the core of most institutional healthcare allocations rather than a high-growth disruptor role. The current investor narrative centers on a third consecutive guidance raise and a path toward $100 billion in annual revenue, driven by booming oncology performance, offset by MedTech softness, biosimilar erosion risk in immunology, and lingering litigation costs. Recent headlines frame the post-Q3 earnings dip as a buying opportunity for dividend-focused long-term investors, with the stock's 64-year dividend increase streak and 2.46% yield anchoring the bull case even as mixed quarterly results and premium valuation draw debate.…
JNJ
Johnson & Johnson
$271.04
Related headlines
JNJ 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Johnson & Johnson's 12-month outlook, with a consensus price target around $279.41 and implied upside of +3.1% versus the current price.
Average Target
$279.41
0 analysts
Implied Upside
+3.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$190 - $320
Analyst target range
Coverage is deep and constructive: 22 analysts cover JNJ with a consensus recommendation of "buy" (mean rating 1.91 on a 1-to-5 scale where 1 is strong buy), and the average target price of $279.41 implies roughly +5.9% upside from the current $263.81. The consensus leans bullish but with tempered enthusiasm — the target sits just below the 52-week high of $281.07, suggesting analysts see limited near-term upside after the 37% one-year run. Recent institutional actions are uniformly positive in direction (HSBC, UBS, Guggenheim, Wells Fargo, Morgan Stanley, RBC, and Raymond James all reiterating Buy/Overweight/Outperform through mid-2026), with only JP Morgan maintaining a Neutral stance in late September.
The target range of $190 to $320 is wide — a $130 spread, or roughly 49% of the current price — signaling meaningful disagreement about the company's trajectory. The $320 high target likely assumes multiple expansion toward 18x forward earnings on accelerating oncology growth and successful pipeline execution toward the $100 billion revenue goal, while the $190 low target prices in MedTech deterioration, biosimilar erosion in immunology, and litigation overhang. The tight clustering of estimated EPS ($17.43 to $18.01) against such a wide price range indicates the dispersion is multiple-driven rather than earnings-driven, meaning sentiment and risk appetite — not fundamentals — will determine where the stock lands; the recent post-earnings dip and reiterated bullish ratings suggest the risk/reward skews modestly positive for patient investors.
Bulls vs Bears: JNJ Investment Factors
The bull case rests on harder evidence: 6.6% revenue growth, expanding margins (gross 68.19%, operating 28.34%), $18.71 billion of trailing free cash flow, a 32.87% ROE, a third guidance raise, and a 23.94-point one-year relative strength advantage over the S&P 500, all reinforced by a 1.91 consensus rating. The bear case is real but narrower — MedTech softness, biosimilar erosion in immunology, a forward PE of 22.71x that exceeds the 18.82x trailing multiple, and a current ratio of 1.03 — and is reflected in the stock's flat three-month performance rather than in deteriorating fundamentals. On balance the bull evidence is currently stronger, but the margin of victory is thin because growth is mid-single-digit and the analyst average target of $279.41 implies only 5.9% upside. The single most important tension is whether oncology momentum in Innovative Medicine can outrun biosimilar erosion in immunology; if pharma growth holds above mid-single digits, the $100 billion revenue path justifies the multiple, but if immunology erodes faster than oncology ramps, the 22.71x forward PE has no support.
Bullish
- Oncology-led pharma growth engine: Innovative Medicine generated $16.38 billion of Q2 2026's $25.31 billion revenue, roughly 65% of the total, and is the segment headlines credit for booming oncology performance. Total revenue grew 6.6% year-over-year, and J&J has now raised full-year guidance for a third consecutive time, with management framing a path toward $100 billion in annual revenue.
- Elite margins with sequential expansion: Q2 2026 gross margin of 68.19% and operating margin of 28.34% both improved from Q1's 66.31% and 26.58%, showing operating leverage even as R&D rose to $3.65 billion. Trailing net margin of 28.46% and ROE of 32.87% are best-in-class for large-cap pharma and underpin the premium multiple.
- Massive free cash flow funds the dividend: Trailing free cash flow of $18.71 billion comfortably covers the $3.23 billion quarterly dividend at a 46.2% payout ratio, leaving room for buybacks and debt reduction. Q2 alone produced $3.39 billion of FCF after $1.32 billion of capex, and the company retired $5.22 billion of debt in the quarter.
- Defensive low-beta profile with strong relative strength: Beta of just 0.206 means JNJ moves roughly 80% less than the market, and its max drawdown over the period was only -10.96%. Despite that defensiveness, the stock is up 37.07% over one year versus 13.13% for the S&P 500, a 23.94 percentage point relative strength advantage.
Bearish
- MedTech weakness driving sales misses: MedTech contributed only $8.93 billion in Q2 and is the segment explicitly flagged as the drag behind the Q3 sales miss that triggered a -5.7% single-day drop on October 13. With pharma at 65% of sales, the device franchise is too small to offset any pharma stumble but large enough to spoil quarterly prints.
- Biosimilar erosion in immunology: Zacks notes biosimilar competitors are gaining ground, a direct threat to the immunology franchise that anchors Innovative Medicine. Because pharma is 65% of revenue, even modest immunology share loss has an outsized effect on consolidated growth that is currently only mid-single-digit at 6.6%.
- Forward PE exceeds trailing, signaling charge-distorted earnings: The stock trades at 22.71x forward earnings versus 18.82x trailing, an unusual inversion that reflects a depressed trailing EPS base of roughly $14.02 against $17.70 forward consensus. Investors are paying a higher multiple on earnings that have not yet been delivered, leaving little cushion if guidance slips.
- Thin liquidity and litigation overhang: The current ratio of 1.03 and quick ratio of 0.81 leave almost no liquidity cushion, and Q4 2025 already showed a -$12.72 billion working capital hit. Legal costs remain a recurring drag cited in coverage, adding unpredictable charges to an otherwise clean earnings stream.
JNJ Technical Analysis
JNJ is in a sustained, powerful uptrend, with the stock up 37.07% over the past year versus just 13.13% for the S&P 500 — a relative strength advantage of 23.94 percentage points. At the current price of $263.81, the stock sits at roughly 82% of its 52-week range (low of $184.66, high of $281.07), positioning it in the upper quartile of its annual band but still about 6.1% below the high. This is a momentum-favorable posture that reflects institutional accumulation rather than overextension, though the proximity to highs leaves limited near-term headroom before resistance. Year-to-date gains of 27.23% confirm the trend is durable rather than a brief spike.
Short-term momentum has decelerated sharply and now diverges from the longer-term trend: the stock is down 1.99% over the past month and essentially flat over three months (+0.16%), badly lagging the S&P 500's +2.85% over the same three-month window (relative strength of -2.69). This divergence — a strong 12-month trend against a soft 1-month and 3-month tape — is consistent with a post-earnings consolidation or mean-reversion pause rather than a trend reversal, given the stock remains 15.96% higher over six months. The recent pullback from the September high of $278.43 to $263.81, including a sharp -5.7% single-day drop on October 13 around Q3 results, suggests profit-taking on the sales miss; the October 22 rebound to $267.61 followed by a -1.42% giveback to $263.81 indicates buyers are defending the low-$250s but lack conviction to reclaim highs.
Key technical levels are well defined: support sits at the 52-week low of $184.66, with a nearer-term floor around the $248–$253 zone tested in mid-October, while resistance is the 52-week high of $281.07. A breakout above $281 would signal resumption of the primary uptrend and likely open a new leg higher, whereas a breakdown below $248 would break the recent higher-low structure and target the $230s. Volatility is exceptionally low — beta of just 0.206 means the stock moves roughly 80% less than the market, making it a defensive ballast position; the modest max drawdown of -10.96% over the period reinforces its low-risk profile, though it also implies limited upside torque in a broad rally.
Beta
0.21
0.21x market volatility
Max Drawdown
-11.0%
Largest decline past year
52-Week Range
$185-$281
Price range past year
Annual Return
+45.0%
Cumulative gain past year
| Period | JNJ Return | S&P 500 |
|---|---|---|
| 1m | -0.3% | +0.9% |
| 3m | +5.9% | +4.1% |
| 6m | +19.3% | +7.2% |
| 1y | +45.0% | +12.4% |
| ytd | +30.7% | +13.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
JNJ Fundamental Analysis
Revenue is growing at a healthy clip: Q2 2026 revenue of $25.31 billion rose 6.6% year-over-year, building on Q1's $24.06 billion and Q4 2025's $24.56 billion, with the trailing four quarters totaling roughly $97.9 billion against analyst estimates of $135.6 billion for the forward year (reflecting a full-year consolidated figure). Segment data shows Innovative Medicine at $16.38 billion and MedTech at $8.93 billion, meaning pharmaceuticals contribute about 65% of sales and are the primary growth engine — consistent with headlines citing booming oncology — while MedTech's $8.93 billion base is the drag flagged in the Q3 sales miss. The trajectory is steady mid-single-digit growth rather than acceleration, which supports a durable but not explosive investment case.
Profitability is robust and improving: Q2 2026 net income was $5.53 billion on a 21.86% net margin, with gross margin of 68.19% and operating margin of 28.34%, up from Q1's 66.31% gross and 26.58% operating margins. The 67.88% trailing gross margin and 27.17% operating margin are elite for large-cap pharma, reflecting pricing power and a high-margin drug mix; net margin of 28.46% on a trailing basis is well above the sector norm. Quarterly EPS of $2.27 (Q2) and $2.14 (Q1) are tracking toward the $17.70 annual consensus, and the margin expansion from Q1 to Q2 signals operating leverage despite rising R&D spend of $3.65 billion in Q2.
The balance sheet is solid but not fortress-like: debt-to-equity of 0.588 is moderate, the current ratio of 1.03 is thin (quick ratio 0.81), and interest coverage of roughly 25x is comfortable. Free cash flow is the standout — $18.71 billion trailing, with Q2 FCF of $3.39 billion after $1.32 billion of capex — comfortably funding the $3.23 billion quarterly dividend (payout ratio 46.2%) and buybacks, though Q2 saw $5.22 billion of debt repayment drain cash by $11.78 billion. ROE of 32.87% is exceptional and confirms high capital efficiency; the main watch item is the low current ratio, which leaves limited liquidity cushion if working capital swings, as seen in Q4 2025's -$12.72 billion working capital hit.
Quarterly Revenue
$25.3B
2026-06
Revenue YoY Growth
+6.6%
YoY Comparison
Gross Margin
68.2%
Latest Quarter
Free Cash Flow
$18.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is JNJ Overvalued?
Because JNJ is solidly profitable (Q2 net income of $5.53 billion), the PE ratio is the appropriate primary metric. The stock trades at 18.82x trailing earnings and 22.71x forward earnings — an unusual inversion where the forward multiple exceeds the trailing, implying the market expects EPS to decline (trailing EPS of roughly $14.02 versus forward consensus of $17.70 actually implies growth, so the gap likely reflects the depressed trailing figure from one-off charges). The forward PE of 22.7x on $17.70 estimated EPS against a $263.81 price suggests the market is pricing in mid-single-digit earnings growth with modest multiple support, and the PEG of 0.21 is strikingly low, flagging the stock as inexpensive relative to its growth rate.
Against the drug manufacturing industry, JNJ's 18.82x trailing PE and 5.35x PS sit at a premium to the broader market but are reasonable for a diversified large-cap pharma with a 28.46% net margin and 32.87% ROE; the 6.18x price-to-book is elevated versus historical norms but justified by asset-light pharma economics. The EV/EBITDA of 12.97x and EV/Sales of 6.78x are moderate for the sector, while the 2.46% dividend yield and 46.2% payout ratio provide income support that pure-growth peers lack. The premium is defensible given best-in-class margins and the $100 billion revenue trajectory, though the 20.55x price-to-cash-flow signals the market is paying up for cash generation.
Historically, JNJ's PE has ranged from roughly 9x to 36x over the past several years, with the current 18.82x trailing sitting near the middle of that band and well below the 28.5x seen in Q2 2026's historical snapshot. The PS ratio of 5.35x is near the low end of its multi-year range (which has run from roughly 15x to 25x on a quarterly snapshot basis), and the PB of 6.18x is near the top of its 4.7x–7.4x recent band. Net, valuation looks fair-to-attractive on earnings and sales but rich on book value — the market is pricing in steady execution rather than heroic optimism, leaving room for re-rating if oncology momentum accelerates.
PE
18.8x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 17x~36x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on a balance sheet that is solid but not fortress-like and on revenue concentration. Debt-to-equity of 0.588 is moderate and interest coverage near 25x is comfortable, but the current ratio of 1.03 and quick ratio of 0.81 leave almost no liquidity cushion, and Q4 2025 already produced a -$12.72 billion working capital hit. Innovative Medicine is roughly 65% of the $25.31 billion quarterly revenue base, so a stumble in immunology or oncology moves the whole company, and Q2 required $3.65 billion of R&D plus $6.43 billion of SG&A to sustain a 6.6% growth rate. The $18.71 billion trailing free cash flow covers the $3.23 billion quarterly dividend at a 46.2% payout, but Q2's $5.22 billion debt repayment drained cash by $11.78 billion, showing how quickly capital allocation can consume the cushion.
Market and competitive risks are dominated by valuation and the MedTech franchise. At 22.71x forward earnings against 18.82x trailing, the market is already paying for earnings that have not yet arrived, and the 6.18x price-to-book sits near the top of its 4.7x-7.4x recent band. MedTech's $8.93 billion base is the segment behind the Q3 sales miss, and Zacks explicitly flags biosimilar competitors gaining ground in immunology, a direct threat to the highest-margin franchise. Beta of 0.206 limits macro sensitivity, but it also means JNJ will lag badly in a broad risk-on rally — it already trails the S&P 500 by 2.69 percentage points over three months — and the Zacks comparison piece favoring UnitedHealth after Q3 highlights sector rotation risk toward faster-growing healthcare names.
A worst-case scenario would combine an immunology biosimilar shock, continued MedTech deterioration, and an adverse litigation outcome, forcing analysts to cut the $17.70 forward EPS consensus and compress the multiple simultaneously. The realistic downside is anchored by the $190 analyst low target, roughly -28% from $263.81, and by the $184.66 52-week low, roughly -30%. A less severe but more probable adverse path is a retest of the $248-$253 support zone tested in mid-October, about -4% to -6%, and a break below $248 would target the $230s, roughly -13%. The historical max drawdown of -10.96% understates tail risk because it covers a benign period; investors should size positions assuming a -25% to -30% bear case is achievable if the immunology franchise cracks.